

Heavy chain disease in non-Ashkenazi or Sephardi Jews!

H.D. Solomons

P.O.Box 64203, Highlands North. 2037

*Correspondence Author: H.D. Solomons, P.O.Box 64203, Highlands North. 2037

Received date: February 06, 2024; Accepted date: March 26 2024; Published date: April 15, 2024

Citation: H.D. Solomons, (2024), Chronotherapies and leiomyomas, *Clinical Oncology Case Reports*, 3(2); DOI: 10.31579/ 2834-5061/15

Copyright: © 2024, H.D. Solomons. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Heavy chain disease is found in Non-Ashkenazi or Sephardi jews.

Studies of people with heavy-chain disease have revealed an association with Sephardi Jews. The gamma heavy chain has been implicated in the disorder. The gamma heavy chain is linked to the Fc fragment of the heavy chain.

Keywords: sephardi jews; immunoglobulin molecule

Introduction

Heavy chain disease is found in Non-Ashkenazi or Sephardi jews.

Studies of people with heavy-chain disease have revealed an association with Sephardi Jews. The gamma heavy chain has been implicated in the disorder. The gamma heavy chain is linked to the Fc fragment of the heavy chain.

Kappa and lambda are the so-called light chains of the immunoglobulin molecule.

These patients may present with Bence Jones protein in their urine.

Heavy chain disease may present with the full gambit of multiple myeloma viz., osteolytic lesions but the IgD variety may have sclerotic zones.

Typically, the IgA variety has a flame appearance to the abnormal plasma cells and typically the perinuclear halo and cart-wheel appearance of the cell is lost.

Salmon and Drury stage the heavy chain disorder from I to IV depending on the degree of invasion and the extent of invasion.

A plasma cell/myeloma cell line with specific heavy chain disease characteristics has been established to determine the Heavy chain locus. Among Sephardi or non-Ashkenazi jews the inheritance is autosomal recessive and affects approximately 2.4 % of the population.

Treatment is with pulsed therapy consisting of melphalan and cyclophosphamide until there are no myeloma cell in the bone marrow aspirate or trephine. Classically on treatment the very elevated erythrocyte sedimentation rate comes down.

Ready to submit your research? Choose ClinicSearch and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At ClinicSearch, research is always in progress.

Learn more <https://clinicsearchonline.org/journals/clinical-oncology-case-reports>

article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.